Abstracts

777 – Time to Stable Sputum Culture Positivity as a Surrogate Endpoint in Phase II/III Tuberculosis Trials

Background Tuberculosis (TB) remains a global health challenge, with an estimated 10.8 million cases reported annually. Although the standard 6-month regimen-comprising isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE)-is effective in clinical trials, its long duration leads to poor adherence and adverse outcomes in practice. Positive culture at month 2 (PCM2) has traditionally served as a milestone endpoint,…

242 – Posttreatment Control Is Associated With Unique Proteomic Signature Before and During ATI

Background Post-treatment controllers (PTCs) are people with HIV (PWH) who achieved low/no viremia during analytical treatment interruption (ATI). Multiple mechanisms could potentially account for post-treatment control. In this study, we leveraged ACTG ATI studies to evaluate proteomic signatures of PTCs and non-controllers (NCs) before and during ATI. Methods We used Olink Inflammatory I and Flex…

527 – Outcomes for Individuals Who Initiate CAB+RPV LA in OPERA With Viral Loads ≥50 vs <50 copies/mL

Background Cabotegravir + rilpivirine long-acting (CAB+RPV LA) is the only complete LA regimen approved for treatment-experienced people with HIV with viral loads (VL) <50 copies/mL (c/mL). This analysis described demographics, clinical characteristics, and virologic outcomes in individuals on CAB+RPV LA stratified by VL at initiation. Methods Treatment-experienced adults who initiated CAB+RPV LA from 21JAN2021-31DEC2024 in OPERA were stratified…

250 – HIV-Associated Sex Differences in the Plasma Proteome Associate With Reservoir Size and CVD Risk

Background Biological sex plays an important role in HIV progression, including during treatment with combined antiretroviral therapy (cART). Earlier research suggests that men generally have larger viral reservoirs, while women experience a higher risk for HIV-associated cardiovascular disease (CVD). To better understand these differences, we compared the plasma proteome in cART treated men and women living with…

832 – HIV Antibodies by Western Blot in Early-Treated Children Living With HIV After a Decade of Treatment

Background Some infants with perinatally-acquired HIV who begin antiretroviral therapy (ART) early in life may test HIV antibody negative in early childhood. We examine whether this is a persisting phenomenon, and factors influencing antibody profile during ART. Methods HIV-1 Western Blot (WB) assays were conducted on blood samples from 215 children living with HIV (CLWH)…

346 – HERV Associate With HIV-DNA and Immune Activation in Blood and GALT of Virologically Suppressed PLWH

Background Despite the efficacy of antiretroviral therapy (ART), many people living with HIV-1 (PLWH) show persistent immune activation and harbour latent reservoirs that hinder long-term disease management. The gut-associated lymphoid tissue (GALT), established early as the main HIV reservoir, is marked by massive CD4+ T-cell loss and high viral replication. Human endogenous retroviruses (HERVs), remnants…

627 – Presence of Kaposi Sarcoma–Associated Herpesvirus Tissue Reservoirs in Seronegative Postmortem Cases

Background Kaposi Sarcoma-Associated Herpesvirus (KSHV) is the causative agent of Kaposi sarcoma (KS) and multiple other diseases that affect people-living-with-HIV-1 (PLWH) and immune suppressed patients. Like HIV-1, KSHV can remain latent in an infected individual and could periodically reactivate to cause diseases upon immunosuppression. While HIV-1 tissue reservoirs in aviremic individuals were recently identified, little…

464 – DTG Compared to DRV/c on the Severity of Neuropsychiatric Effects at 24 Weeks of Treatment in PWH

Background Integrase strand transfer inhibitors (INSTIs) are linked to neuropsychiatric adverse events (NPS). This study aimed to evaluate changes in NPS in antiretroviral therapy (ART)-naïve people living with HIV (PWH) who reported baseline NPS symptoms and initiated treatment with either Dolutegravir (DTG) or Darunavir/Cobicistat (DRV/c), both combined with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC). Methods A randomized,…

468 – Proteomic Correlates of Depressive Symptoms: Insights From the RV254/SEARCH010 Acute HIV Thai Cohort

Background Depressive disorders occur nearly three times more often among people with HIV (PWH) compared to the general population and predict poorer outcomes along the HIV care continuum. Identifying biological pathways underlying depressive symptoms (DS) during acute HIV infection (AHI) may inform strategies to improve long-term outcomes. Circulating proteins released during AHI activate inflammatory cascades…